| Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis JS Eaton, ZP Lin, AC Sartorelli, ND Bonawitz, GS Shadel The Journal of clinical investigation 117 (9), 2723-2734, 2007 | 200 | 2007 |
| p53 protein aggregation promotes platinum resistance in ovarian cancer Y Yang-Hartwich, MG Soteras, ZP Lin, J Holmberg, N Sumi, V Craveiro, ... Oncogene 34 (27), 3605-3616, 2015 | 155 | 2015 |
| The pharmacological phenotype of combined multidrug-resistance mdr1a/1b-and mrp1-deficient mice DR Johnson, RA Finch, ZP Lin, CJ Zeiss, AC Sartorelli Cancer research 61 (4), 1469-1476, 2001 | 128 | 2001 |
| Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response ZP Lin, YL Zhu, DR Johnson, KP Rice, T Nottoli, BC Hains, J McGrath, ... Molecular pharmacology 73 (1), 243-251, 2008 | 119 | 2008 |
| Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53 (–/–) HCT-116 colon cancer cells to DNA-damaging agents … ZP Lin, MF Belcourt, JG Cory, AC Sartorelli Journal of Biological Chemistry 279 (26), 27030-27038, 2004 | 99 | 2004 |
| Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-κB activation in drug resistance ZP Lin, YC Boller, SM Amer, RL Russell, KA Pacelli, SR Patierno, ... Cancer research 58 (14), 3059-3065, 1998 | 91 | 1998 |
| Targeting cyclin-dependent kinases for treatment of gynecologic cancers ZP Lin, YL Zhu, ES Ratner Frontiers in oncology 8, 303, 2018 | 63 | 2018 |
| Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer ES Ratner, AC Sartorelli, ZP Lin Current opinion in oncology 24 (5), 564-571, 2012 | 57 | 2012 |
| Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC. 06 H Zeng, ZP Lin, AC Sartorelli Biochemical pharmacology 68 (5), 911-921, 2004 | 54 | 2004 |
| Triapine Disrupts CtIP-mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase Inhibitors ZP Lin, ES Ratner, ME Whicker, Y Lee, AC Sartorelli Molecular Cancer Research 12 (3), 381-393, 2014 | 50 | 2014 |
| Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper (II) complexes K Ishiguro, ZP Lin, PG Penketh, K Shyam, R Zhu, RP Baumann, YL Zhu, ... Biochemical pharmacology 91 (3), 312-322, 2014 | 47 | 2014 |
| Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress ZP Lin, MF Belcourt, R Carbone, JS Eaton, PG Penketh, GS Shadel, ... Biochemical pharmacology 73 (6), 760-772, 2007 | 38 | 2007 |
| Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair ES Ratner, YL Zhu, PG Penketh, J Berenblum, ME Whicker, PH Huang, ... British Journal of Cancer 114 (7), 777-786, 2016 | 32 | 2016 |
| Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer ZP Lin, YL Zhu, YC Lo, J Moscarelli, A Xiong, Y Korayem, PH Huang, ... PLoS One 13 (11), e0207399, 2018 | 29 | 2018 |
| MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib ME Whicker, ZP Lin, R Hanna, AC Sartorelli, ES Ratner BMC cancer 16, 1-12, 2016 | 24 | 2016 |
| Comparative Study of the Importance of Multidrug Resistance-associated Protein 1 and P-Glycoprotein to Drug Sensitivity in Immortalized Mouse Embryonic Fibroblasts. ZP Lin, DR Johnson, RA Finch, MG Belinsky, GD Kruh, AC Sartorelli Molecular cancer therapeutics 1 (12), 1105-1114, 2002 | 24 | 2002 |
| Prostaglandin A1 inhibits stress-induced NF-kappaB activation and reverses resistance to topoisomerase II inhibitors. YC Boller, LM Brandes, RL Russell, ZP Lin, SR Patierno, KA Kennedy Oncology research 12 (9-10), 383-395, 2000 | 21 | 2000 |
| Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage ZP Lin, Y Lee, F Lin, MF Belcourt, P Li, JG Cory, PM Glazer, AC Sartorelli Molecular Pharmacology 80 (6), 1000-1012, 2011 | 20 | 2011 |
| Age-related differences in vincristine toxicity and biodistribution in wild-type and transporter-deficient mice. T Muramatsu, DR Johnson, RA Finch, LK Johnson, JJ Leffert, ZP Lin, ... Oncology research 14 (7-8), 331-343, 2004 | 20 | 2004 |
| Reversal of Physiological Stress-Induced Resistance to Topoisomerase II Inhibitors Using an Inducible Phosphorylation Site-Deficient Mutant of IκBα LM Brandes, ZP Lin, SR Patierno, KA Kennedy Molecular Pharmacology 60 (3), 559-567, 2001 | 18 | 2001 |
Margaret WhickerGynecologic Oncology Fellow, University of PennsylvaniaVerified email at pennmedicine.upenn.edu
